Hypofractionated Radiotherapy for Recurrent DIPG
| Status: | Enrolling by invitation |
|---|---|
| Conditions: | Brain Cancer |
| Therapuetic Areas: | Oncology |
| Healthy: | No |
| Age Range: | Any - 30 |
| Updated: | 2/17/2019 |
| Start Date: | January 31, 2018 |
| End Date: | July 31, 2023 |
Feasibility Study of Hypofractionated Radiotherapy in the Setting of Recurrent Diffuse Intrinsic Pontine Glioma
This study evaluates the feasibility of hypofractionated radiotherapy (RT) in the palliative
treatment of recurrent diffuse intrinsic pontine glioma (DIPG). Participants will receive 15
Gy in 3 fractions as opposed to the standard 20 Gy in 10 fractions.
treatment of recurrent diffuse intrinsic pontine glioma (DIPG). Participants will receive 15
Gy in 3 fractions as opposed to the standard 20 Gy in 10 fractions.
Inclusion Criteria:
1. Patients must be ≤30 years of age
2. Patients must have a diagnosis of progressive DIPG.
3. Received prior IMRT based definitive radiotherapy to a dose of ≥54 Gy.
4. The patient and or parent/legal guardian must be physically and mentally capable of
signing the consent form of their own volition.
5. Steroids dosage must be unchanged for 5 days.
6. No Bevacizumab within 21 days (Half-life 11 days ~)
Exclusion Criteria:
1. Patients with incomplete medical records
2. Patients with prior history of reirradiation for DIPG
3. Life expectancy < or equal to 1 month
4. Pregnant women
5. Age >30
6. Prisoners
7. Concurrent systemic therapy at the time of reirradiation
8. Physically or mentally incapable of signing the consent form of their own volition
9. < 6 mos time interval between completion of initial RT to start of reRT.
We found this trial at
1
site
University of Cincinnati The University of Cincinnati offers students a balance of educational excellence and...
Click here to add this to my saved trials
